Amgen Statistics
Total Valuation
Amgen has a market cap or net worth of $141.58 billion. The enterprise value is $192.96 billion.
| Market Cap | 141.58B |
| Enterprise Value | 192.96B |
Important Dates
The next estimated earnings date is Tuesday, February 4, 2025, after market close.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | Feb 14, 2025 |
Share Statistics
Amgen has 537.53 million shares outstanding. The number of shares has increased by 0.42% in one year.
| Current Share Class | 537.53M |
| Shares Outstanding | 537.53M |
| Shares Change (YoY) | +0.42% |
| Shares Change (QoQ) | +0.18% |
| Owned by Insiders (%) | 0.15% |
| Owned by Institutions (%) | 78.42% |
| Float | 536.16M |
Valuation Ratios
The trailing PE ratio is 33.62 and the forward PE ratio is 12.75. Amgen's PEG ratio is 2.55.
| PE Ratio | 33.62 |
| Forward PE | 12.75 |
| PS Ratio | 4.34 |
| Forward PS | 4.05 |
| PB Ratio | 18.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.53 |
| P/OCF Ratio | 19.51 |
| PEG Ratio | 2.55 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.76, with an EV/FCF ratio of 30.71.
| EV / Earnings | 45.62 |
| EV / Sales | 5.93 |
| EV / EBITDA | 15.76 |
| EV / EBIT | 28.92 |
| EV / FCF | 30.71 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 8.02.
| Current Ratio | 1.32 |
| Quick Ratio | 0.80 |
| Debt / Equity | 8.02 |
| Debt / EBITDA | 4.86 |
| Debt / FCF | 9.61 |
| Interest Coverage | 2.07 |
Financial Efficiency
Return on equity (ROE) is 55.72% and return on invested capital (ROIC) is 6.13%.
| Return on Equity (ROE) | 55.72% |
| Return on Assets (ROA) | 4.60% |
| Return on Capital (ROIC) | 6.13% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | $158,427 |
| Employee Count | 26,700 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 2.07 |
Taxes
In the past 12 months, Amgen has paid $449.00 million in taxes.
| Income Tax | 449.00M |
| Effective Tax Rate | 9.60% |
Stock Price Statistics
The stock price has decreased by -5.41% in the last 52 weeks. The beta is 0.54, so Amgen's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | -5.41% |
| 50-Day Moving Average | 297.17 |
| 200-Day Moving Average | 305.01 |
| Relative Strength Index (RSI) | 31.29 |
| Average Volume (20 Days) | 5,151,639 |
Short Selling Information
The latest short interest is 11.14 million, so 2.07% of the outstanding shares have been sold short.
| Short Interest | 11.14M |
| Short Previous Month | 9.81M |
| Short % of Shares Out | 2.07% |
| Short % of Float | 2.08% |
| Short Ratio (days to cover) | 2.89 |
Income Statement
In the last 12 months, Amgen had revenue of $32.53 billion and earned $4.23 billion in profits. Earnings per share was $7.83.
| Revenue | 32.53B |
| Gross Profit | 19.71B |
| Operating Income | 6.67B |
| Pretax Income | 3.53B |
| Net Income | 4.23B |
| EBITDA | 12.25B |
| EBIT | 6.67B |
| Earnings Per Share (EPS) | $7.83 |
Balance Sheet
The company has $9.01 billion in cash and $60.40 billion in debt, giving a net cash position of -$51.39 billion or -$95.60 per share.
| Cash & Cash Equivalents | 9.01B |
| Total Debt | 60.40B |
| Net Cash | -51.39B |
| Net Cash Per Share | -$95.60 |
| Equity (Book Value) | 7.53B |
| Book Value Per Share | 14.00 |
| Working Capital | 6.45B |
Cash Flow
In the last 12 months, operating cash flow was $7.26 billion and capital expenditures -$974.00 million, giving a free cash flow of $6.28 billion.
| Operating Cash Flow | 7.26B |
| Capital Expenditures | -974.00M |
| Free Cash Flow | 6.28B |
| FCF Per Share | $11.69 |
Margins
Gross margin is 60.59%, with operating and profit margins of 20.51% and 13.00%.
| Gross Margin | 60.59% |
| Operating Margin | 20.51% |
| Pretax Margin | 14.38% |
| Profit Margin | 13.00% |
| EBITDA Margin | 37.64% |
| EBIT Margin | 20.51% |
| FCF Margin | 19.31% |
Dividends & Yields
This stock pays an annual dividend of $9.52, which amounts to a dividend yield of 3.62%.
| Dividend Per Share | $9.52 |
| Dividend Yield | 3.62% |
| Dividend Growth (YoY) | 5.67% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 121.54% |
| Buyback Yield | -0.42% |
| Shareholder Yield | 3.20% |
| Earnings Yield | 2.99% |
| FCF Yield | 4.44% |
Analyst Forecast
The average price target for Amgen is $329.05, which is 24.93% higher than the current price. The consensus rating is "Buy".
| Price Target | $329.05 |
| Price Target Difference | 24.93% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (5Y) | 5.52% |
| EPS Growth Forecast (5Y) | 12.66% |
Stock Splits
The last stock split was on November 22, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Nov 22, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Amgen has an Altman Z-Score of 1.44 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.44 |
| Piotroski F-Score | 6 |